We use cookies to improve your experience on our website. Read about how we use cookies and how you can control them by reviewing the Cookie section of our Privacy Policy. By continuing to use this website, you consent to our use of these cookies.

  • BMS Science Search BMS recruiting trials
  • Bolder Science Powered by ClinicalTrials.gov
    This website is intended for healthcare professionals
    This website is intended for healthcare professionals
  • Sign Up
  • Log In
  • Sign up for an account to save the trials you’re interested in following. You can use one account across both BMS Science and Bolder Science to track clinical trials worldwide.
Sign up for an account to save the trials you’re interested in following. You can use one account across both BMS Science and Bolder Science to track clinical trials worldwide.
 
  • Clinical Trials
  • Molecular Pathways
  • About BMS Science
Cancel
    Bromodomain and extra-terminal motif (BET) proteins
    • Hematology
    • BCMA (CAR T, TCE, ADC)
    • BET
    • CD19 (CAR T)
    • CD47
    • CRBN
    • DNA methyltransferase
    • HDAC
    • IDH
    • JAK2
    • LSD1
    • PD-1
    • SLAMF7
    • Smad2/3

    BET

    Gene expression is controlled through access to DNA, which is mediated by epigenetic modifications to histones.1,2  Bromodomain and extra-terminal motif (BET) proteins are epigenetic “readers” that bind to acetylated lysine residues on histone tails.3,4 BET proteins regulate initiation and continuation of transcription of key cell cycle control genes by recruiting and interacting with transcription factors and
    RNA polymerase II.5-7

    Additionally, BET proteins can “bookmark” genes by remaining bound to chromatin during mitosis, thereby speeding reinitiation of transcription.5 Super-enhancers, which are noncoding regions of DNA critical to oncogene transcription and maintenance of cancer cell identity, are observed to have high densities of BET binding.8

    Preclinical studies suggest that inhibition of BET may result in the downregulation of key cell cycle regulatory genes, cell cycle arrest, and apoptosis of tumor cells.4,9

    BMS is investigating BET inhibitors for the treatment of solid tumors and hematologic malignancies.

    References

    1. Bannister A, et al. Cell Research. 2011;21:381-395. PMID: 21321607
    2. Ververis K, et al. Biologics. 2013;7:47-60. PMID: 23459471
    3. Taniguchi Y. Int J Mol Sci. 2016;17:1849. PMID: 27827996
    4. Doroshow DB, et al. Ann Oncol. 2017;28:1776-1787. PMID: 28838216
    5. Devaiah BN, et al. Transcription. 2013;4:13-17. PMID: 23131666
    6. Yang Z, et al. Mol Cell Biol. 2008;28:967-976. PMID: 18039861
    7. Mochizuki K, et al. J Biol Chem. 2008;83:9040-9048. PMID: 18223296
    8. Sengupta S, et al. Trends Cancer. 2017;3:269-281. PMID: 28718439
    9. Dawson MA, et al. Nature. 2011;478:529-533. PMID: 21964340
    Bristol Myers Squibb logo
    • Legal Notice
    • Privacy Policy
    • Contact Us
    • Sitemap
    466-US-2200141 07/22
    © 2022 BMS Science 466-US-2100214 05/22
    BMS Science is a registered trademark of Bristol-Myers Squibb Company.

    You are now leaving www.BMSscience.com. BMS is not responsible for the content on third-party website

    Continue Cancel
    close-icon

    Log In

    Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

    Forgot Password

    Don't have an account? Sign Up

    close-icon

    Please enter your email address.

    You will receive a link to create a new password via email.

    Log In

    close-icon

    Create Account

    Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

    • 8 characters minimum
    • First character cannot be a number
    • Last character cannot be a number

    By clicking submit, you agree to the BMS Privacy Policy and Terms & Conditions

    close-icon

    Previous Next skip